Validation analysis of a composite real-world mortality endpoint for patients with cancer in the United States.

Validation analysis of a composite real-world mortality endpoint for patients with cancer in the United States.
复制标题

DOI:
10.1111/1475-6773.13669
复制
发表时间:
2021-12
影响因子:
3.4
通讯作者:
Parrinello CM
Parrinello CM
中科院分区:
医学3区
文献类型:
--
作者:
Zhang Q;Gossai A;Monroe S;Nussbaum NC;Parrinello CM

文献摘要

参考文献

被引文献

相似文献

我们扩展了之前对适用于真实的以证据为中心的肿瘤学研究的死亡率变量的评估。我们使用了一个全国性的电子健康记录(EHR)衍生的去识别数据库。我们纳入了2011年1月1日至2017年12月31日期间患有18种癌症类型中至少1种的患者。将患者水平的结构化数据(EHR、讣告和社会保障死亡指数)和非结构化EHR数据(摘要)相关联,以生成复合死亡率变量。我们将灵敏度、特异性、阳性预测值(PPV)、阴性预测值(NPV)和±15天一致率与国家死亡指数(NDI)进行了基准测试。使用Kaplan-Meier方法估计真实的世界总生存期(rwOS)。我们使用接受下一代测序检测的较小患者队列进行了敏感性分析。与18种癌症类型的NDI相比(总体N = 160 436):灵敏度,83.9%-91.5%(17/18种癌症类型的灵敏度≥85.0%);特异性,93.5%-99.7%; PPV,96.3%-98.3%; NPV,75.0%-98.7%; ±15天一致率,95.6%-97.6%;而rwOS估计值的中位数从2.8%到12.7%不等。敏感性分析结果(n = 17 540)与主要分析结果一致。在分析的所有癌症类型中,该复合死亡率变量显示出高灵敏度、特异性、PPV、NPV和±15天一致性,并且与基于NDI的结果相比,产生的中位rwOS值适度高估。
We expanded the previous assessment of a mortality variable suited for real‐world evidence‐focused oncology research. We used a nationwide electronic health record (EHR)‐derived de‐identified database. We included patients with at least 1 of 18 cancer types between January 1, 2011 and December 31, 2017. Patient‐level structured data (EHRs, obituaries, and Social Security Death Index) and unstructured EHR data (abstracted) were linked to generate a composite mortality variable. We benchmarked sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and ±15‐day agreement against the National Death Index (NDI). Real‐world overall survival (rwOS) was estimated using the Kaplan‐Meier method. We performed sensitivity analyses using a smaller patient cohort that underwent next‐generation sequencing testing. Compared with the NDI across 18 cancer types (overall N = 160 436): sensitivity, 83.9%‐91.5% (17/18 cancer types had sensitivity ≥85.0%); specificity, 93.5%‐99.7%; PPV, 96.3%‐98.3%; NPV, 75.0%‐98.7%; ±15‐day agreement, 95.6%‐97.6%; and median rwOS estimates ranging from 2.8% to 12.7% greater. Sensitivity analysis results (n = 17 540) were consistent with the main analysis. Across all cancer types analyzed, this composite mortality variable showed high sensitivity, specificity, PPV, NPV, and ±15‐day agreement, and yielded median rwOS values modestly overestimated when compared to NDI‐based results.
DOI: 10.1111/1475-6773.12872
发表时间: 2018-12
影响因子: 3.4
作者:
Curtis MD;Griffith SD;Tucker M;Taylor MD;Capra WB;Carrigan G;Holzman B;Torres AZ;You P;Arnieri B;Abernethy AP
通讯作者: Abernethy AP
DOI: 10.1200/jco.2011.38.7589
发表时间: 2012-09-10
影响因子: 45.3
作者:
Ibrahim, Joseph G.;Chu, Haitao;Chen, Ming-Hui
通讯作者: Chen, Ming-Hui
DOI: 10.1002/sim.4117
发表时间: 2011-02-20
影响因子: 2
作者:
Siannis, Fotios
通讯作者: Siannis, Fotios
DOI: 10.1093/oxfordjournals.aje.a116664
发表时间: 1993-01-15
影响因子: 5
作者:
CALLE, EE;TERRELL, DD
通讯作者: TERRELL, DD
DOI: 10.1002/pds.4758
发表时间: 2019-05-01
影响因子: 2.6
作者:
Carrigan, Gillis;Whipple, Samuel;Capra, William B.
通讯作者: Capra, William B.